Matthew Maurer

Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53 (1998)

Resnick-Silverman, Lois, St. Clair, Selvon, Maurer, Matthew, Zhao, Kathy, Manfredi, James J.

Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53

Resnick-Silverman, Lois, St. Clair, Selvon, Maurer, Matthew, Zhao, Kathy, Manfredi, James J.

There are two response elements for p53 in the promoter of the gene for the cyclin-dependent kinase inhibitor p21. The binding of p53 to the 5′ site was enhanced by incubation with monoclonal...

Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53

Resnick-Silverman, Lois, St. Clair, Selvon, Maurer, Matthew, Zhao, Kathy, Manfredi, James J.

There are two response elements for p53 in the promoter of the gene for the cyclin-dependent kinase inhibitor p21. The binding of p53 to the 5′ site was enhanced by incubation with monoclonal...

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

Saal, Lao H., Johansson, Peter, Holm, Karolina, Gruvberger-Saal, Sofia K., She, Qing-Bai, Maurer, Matthew, ...

Pathway-specific therapy is the future of cancer management. The oncogenic phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in solid tumors; however, currently, no reliable test...